<DOC>
	<DOCNO>NCT00004258</DOCNO>
	<brief_summary>RATIONALE : EMD 121974 may stop growth cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness EMD 121974 treat patient locally advanced metastatic cancer .</brief_summary>
	<brief_title>EMD 121974 Treating Patients With Locally Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability EMD 121974 patient advanced metastatic cancer . II . Correlate various surrogate marker antiangiogenic activity EMD 121974 therapy include magnetic resonance image PET scan , serum assay various angiogenic antiangiogenic factor , serum urine marker calcium metabolism , tumor biopsy . OUTLINE : This dose-escalation study . Patients receive EMD 121974 IV 1 hour twice weekly 4 week . Treatment continue additional course absence unacceptable toxicity . Patients stable respond disease may continue therapy indefinitely past 2 course disease progression . Cohorts 3-6 patient receive escalate dos EMD 121974 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow every 3 month first year , every 4 month thereafter disease progression . PROJECTED ACCRUAL : A total 31-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced metastatic cancer consider incurable standard curative therapy exist No primary CNS malignancy Measurable evidence residual , recurrent , metastatic disease No prior CNS metastases residual abnormal finding neuroradiologic study Prior CNS metastases allow provide least 6 month definitive therapy normal CT MRI brain PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Hemoglobin least 9 mg/dL ( may post transfusion ) Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal PT/PTT normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require parenteral antibiotic No document abnormal CNS exam seizure disorder major neuropsychiatric problem PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior hematopoietic growth factor cytokine therapy recover No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( least 6 week since prior nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid except steroid replacement therapy chronic low dose ( great 10 mg/day oral prednisone ) therapy nonmalignant condition No concurrent hormonal therapy except oral contraceptive hormonal replacement therapy Radiotherapy : At least 2 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 2 week since prior surgery recover Other : At least 4 week since prior investigational drug No concurrent oral parenteral anticoagulant except anticoagulant central venous catheter include low dose warfarin ( 12 mg/day ) and/or heparin No concurrent oral COX2 specific inhibitor ( e.g. , celecoxib rofecoxib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>